Kanger never said it was working on govt procurement of vaccines. All the while, the plan is to distribute for private purchase. Now that the govt has cleared the air, Kanger looks like its at the forefront with approval from MosTI to bring in Sinopharm to Malaysia. Zuellig Pharma appointed for distribution for private use. NPRA is a must but like most countries approval can be expedited on emergency ground. With the latest PP placed at 0.16, it is a very fair proposal and Kanger will have the funds to pull through the vaccine project with sufficient funding. Anyway,
No Middlemen In Government’s Covid-19 Vaccine Deals: Khairy
By CodeBlue | 07 December 2020
Khairy Jamaluddin says the government’s RM3 billion allocation is not just for Pfizer’s vaccine alone, but for all Covid-19 vaccines to immunise 70% of the population, covering procurement, storage, and transport.
Companies Are Free To Pursue Any Vaccine Deals, But It All Comes Down To NPRA’s Approval
The minister also said that any private companies can make private deals with international vaccine companies, but those deals are not related to the government’s vaccine agreements.
“Any company can discuss with any international companies to be their agent, distributor, etc and we cannot control if they want to make commercial arrangements with any companies or vaccine manufacturers,” the Umno lawmaker said.
“If they do not get approval from Clinical Research Malaysia, for example, they can’t run clinical trials here. If they do not get approval from the National Pharmaceutical Regulatory Agency (NPRA) which is under the Ministry of Health (MOH), they cannot bring in the vaccine into Malaysia.”
what happen PP another 20% again at @16sen. like this how lah. Retailers keep buying they keep issuing PP shares. Like this market how to absorb so much shares lah. Mgmt want to kill the price from moving up kah. correct?
@greenland You are absolutely right that approval can be expedited By NPRA on emergency grounds. There is a new approval procedure / pathway for that was just developed to be applied during pandemic situations...
khairy explanation very straight forward. you want to sign what MOU to bring in vaccines is your right. but Vaccine must approved by NPRA. no approval not allowed to bring into Msia. Those sign contract in advanced and made payment or setup facilities will have some risks. The risk NPRA not approve the vaccine they want to bring in. at the end lose everything. very straight forward. correct?
9. RISK FACTORS Kanger does not expect any material risk arising from the Agreement other than the normal business and industry risks such as regulatory approvals of local authorities, logistics handling of the vaccines and competitors. Even though Kanger may not have the prior experience to undertake the distribution of Covid- 19 vaccines, Kanger will hire an experienced team to mitigate the risks.
10. There will be no costs due to Sinopharm Hunan Changde, in the event Kanger is unable to enter into any dealership/distributorship agreement(s) for the distribution of Covid-19 vaccines.
Actually kanger bamboo flooring business far more important than Vaccine one off type of business. The amount invested over Rm100mil far more important than vaccine business kanger can generate from the sales and profit. As more companies are eying the vaccine cake. So far counting is 12 including kanger. more cut throat price war will happen and erode the profit. why you all keep talking about the vaccine not bamboo flooring and other bamboo related businesses. correct?
@UlarSawa Yes bamboo is profitable. There is a high demand for bamboo flooring and other bamboo related products within China alone. Currently China continues to be the only economy in the world to show positive growth in 2020 as its GDP is predicted to expand 1.9 percent this year, according to the latest economic outlook released by the International Monetary Fund (IMF).
On behalf of the Board, UOBKH wishes to announce that the Board had on 7 December 2020 resolved to fix the issue price for the 3rd tranche of the Private Placement at RM0.1593 per Placement Share.
The issue price of RM0.1593 per Placement Share represents a discount of approximately 9.95% to the 5-day VWAP of Kanger Shares up to and including 4 December 2020, being the last traded day of Kanger Shares immediately preceding the price-fixing date of RM0.1769 per Kanger Share.
At the same time, Khairy said if private companies failed to get relevant approvals such as the National Pharmaceutical Regulatory Agency under the Health Ministry, they cannot bring Covid-19 vaccines into Malaysia.
“So I want to say this to market investors. The announcement made by these (private) companies does not mean that they have an allocation from the government.
“The government’s deal is only with Pfizer and Covax, and does not go through any third party or middleman,” he added.
These are my tots for the day. Don't mind sharing.
I have been telling vaccine is the shining star bonus, the cash cow is its ongoing bamboo business. But people all look for vaccine rocket only, they don't bother with ongoing business. Guess there's big expectation difference. My view is when we buy in cheap and in bulk, we must look at potential risks and fall backs as I don't want to CL. For eg. if for whatever reason, vaccine deal fell through (finger crossed), what then? Is bamboo business enough to pull us through? Or is Kanger morphing into a political counter? Or Setiakon / Dato Kuan trying for a backdoor listing as it is not normal for a successful construction co. to be a substantial shareholder of a listed co. without any ambitions.
Ular, Founder of Kanger is the MD himself, a China national, based in China, JV with Chinese local Government...workers also got ESOS...they are serious businessmen. You think got hanky panky or not?
All go for goreng stock. Why don't get some blue chip like carlsberg.. U never able guess goreng stock.. Etc.. Kanger may sky rock up tomorrow after release many negative news
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
greenland
378 posts
Posted by greenland > 2020-12-07 19:16 | Report Abuse
Kanger never said it was working on govt procurement of vaccines. All the while, the plan is to distribute for private purchase. Now that the govt has cleared the air, Kanger looks like its at the forefront with approval from MosTI to bring in Sinopharm to Malaysia. Zuellig Pharma appointed for distribution for private use.
NPRA is a must but like most countries approval can be expedited on emergency ground.
With the latest PP placed at 0.16, it is a very fair proposal and Kanger will have the funds to pull through the vaccine project with sufficient funding.
Anyway,